Supreme Court Denies AMRN's Petition for Cert
As expected, the Supreme Court DENIED AMRN's Petition for Cert. This means that the U.S. Supreme Court will not review the affirmation of the Federal Circuit of the Nevada District Court's ruling that AMRN's asserted patents were invalid. This is the end of the road and confirmed loss for AMRN for Case 1 (See my prior article on BPIQ.com) and the patents asserted in the ANDA litigation. However, keep in mind that there is the very active recent patent infringement lawsuit of AMRN against Hikma and Health Net (Case 2 below) as well as the important case of GSK vs. Teva (Case 3 below), which has an imminent ruling on the rehearing. See my prior article on BPIQ.com for more details.
#AMRN #VASCEPA #ICOSAPENTETHYL
10 Views